CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 119 filers reported holding CLOVIS ONCOLOGY INC in Q2 2022. The put-call ratio across all filers is 0.93 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $299,000 | -10.7% | 166 | 0.0% | 0.00% | – |
| Q1 2022 | $335,000 | -25.6% | 166 | 0.0% | 0.00% | – |
| Q4 2021 | $450,000 | -39.2% | 166 | 0.0% | 0.00% | – |
| Q3 2021 | $740,000 | -15.5% | 166 | 0.0% | 0.00% | – |
| Q2 2021 | $876,000 | -24.8% | 166 | 0.0% | 0.00% | – |
| Q1 2021 | $1,165,000 | +46.2% | 166 | 0.0% | 0.00% | – |
| Q4 2020 | $797,000 | -17.7% | 166 | 0.0% | 0.00% | – |
| Q3 2020 | $968,000 | -13.6% | 166 | 0.0% | 0.00% | – |
| Q2 2020 | $1,120,000 | +6.1% | 166 | 0.0% | 0.00% | – |
| Q1 2020 | $1,056,000 | -94.7% | 166 | -92.1% | 0.00% | -100.0% |
| Q4 2019 | $19,797,000 | +139.9% | 2,100 | 0.0% | 0.00% | +300.0% |
| Q3 2019 | $8,251,000 | -73.6% | 2,100 | 0.0% | 0.00% | -80.0% |
| Q2 2019 | $31,215,000 | -40.1% | 2,100 | 0.0% | 0.01% | -50.0% |
| Q1 2019 | $52,102,000 | +38.2% | 2,100 | 0.0% | 0.01% | +42.9% |
| Q4 2018 | $37,704,000 | -38.8% | 2,100 | 0.0% | 0.01% | -41.7% |
| Q3 2018 | $61,654,000 | -35.4% | 2,100 | 0.0% | 0.01% | -25.0% |
| Q2 2018 | $95,447,000 | – | 2,100 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,997,826 | $10,834,000 | 0.69% |
| Ikarian Capital, LLC | 1,112,669 | $3,016,000 | 0.45% |
| Versant Venture Management, LLC | 101,855 | $276,000 | 0.15% |
| Virtus ETF Advisers LLC | 60,836 | $165,000 | 0.06% |
| EMFO, LLC | 21,500 | $58,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| PINNACLE ASSOCIATES LTD | 706,336 | $1,914,000 | 0.03% |
| XTX Topco Ltd | 20,920 | $57,000 | 0.03% |
| State of Wyoming | 25,419 | $69,000 | 0.03% |